All In Biotech

Drug Trial Radar · NCT00153101

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

ONTARGET ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial A Large, Simple Randomized Trial of an Angiotensin II Receptor Antagonist (Telmisartan) and an ACE-Inhibitor (Ramipril) in Patients at High Risk for Cardiovascular Events and TRANSCEND Telmisartan Randomized AssessmeNt Study in aCE iNtolerant Subjects With Cardiovascular Disease. A Parallel Study Comparing the Effects of Telmisartan With Placebo and Outcomes in Patients at High Risk for Cardiovascular Events and Intolerant to ACE-I.

Last checked: Nov 19, 2026Latest source record: May 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31,546

Actual

Start

Nov 2001

Primary completion

Jun 2008

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Model
Parallel
Primary purpose
Prevention
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Ongoing Telmisartan Alone and in combination wiht Ramipril Global Endpoint trial (ONTARGET): The primary objectives are to determine if (a) telmisartan 80mg daily and ramipril 10mg daily combination therapy is more effective in reducing the composite endpoint of Cardiovascular Death (CV) death, Myocardial infarction (MI), stroke or hospitalization for Congestive Heart Failure (CHF) compared with ramipril 10mg alone; and (b) telmisartan 80mg daily is at least as effective as (i.e. not less effective than) ramipril 10mg daily, on this endpoint. Telmisartan Randomised Assessment Study in Angiotension converting Enzyme inhibitor intolerant subjects with Cardiovascular Disease. (TRANSCEND): The primary objective of the study is to determine if treatment with telmisartan 80mg daily is superior to placebo reducing the composite endpoint of Cardiovascular Death (CV), Myocardial Infarction ( MI)I, stroke or hospitalization for Congestive Heart Failure (CHF) in patients who are intolerant to Angiotension Converting Enzyme inhibitors.

Conditions

  • Cardiovascular Diseases

Interventions

  • TelmisartanDrug

  • Combination of Telmisartan and RamiprilDrug

  • RamiprilDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ONTARGET. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart FailureTime frame: 56 months
  2. ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy PatientsTime frame: 56 months
  3. TRANSCEND. Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non-fatal Stroke and Hospitalization for Congestive Heart FailureTime frame: 56 months

Locations

732 sites in 41 countries. Site status is shown where the registry gives one.

  • 502.373.0256 Boehringer Ingelheim Investigational Site

    Athens, Alabama

  • 502.373.0251 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 502.373.0182 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 502.373.0188 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 502.373.0189 Boehringer Ingelheim Investigational Site

    Tucson, Arizona

  • 502.373.0177 Boehringer Ingelheim Investigational Site

    Tuscon, Arizona

  • 502.373.0209 Boehringer Ingelheim Investigational Site

    Bentonville, Arkansas

  • 502.373.0173 Boehringer Ingelheim Investigational Site

    Concord, California

  • 502.373.0266 Boehringer Ingelheim Investigational Site

    Harbor City, California

  • 502.373.0283 Boehringer Ingelheim Investigational Site

    Loma Linda, California

  • 502.373.0180 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 502.373.0175 Boehringer Ingelheim Investigational Site

    Sacramento, California

  • 502.373.0165 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 502.373.0228 Boehringer Ingelheim Investigational Site

    San Leandro, California

  • 502.373.0205 Boehringer Ingelheim Investigational Site

    Sylmar, California

  • 502.373.0277 Boehringer Ingelheim Investigational Site

    West Hills, California

  • 502.373.0226 Boehringer Ingelheim Investigational Site

    Bridgeport, Connecticut

  • 502.373.0174 Boehringer Ingelheim Investigational Site

    Farmington, Connecticut

  • 502.373.0258 Boehringer Ingelheim Investigational Site

    Washington D.C., District of Columbia

  • 502.373.0179 Boehringer Ingelheim Investigational Site

    Gainesville, Florida

  • 502.373.0183 Boehringer Ingelheim Investigational Site

    Palm Harbor, Florida

  • 502.373.0240 Boehringer Ingelheim Investigational Site

    Panama City, Florida

  • 502.373.0171 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 502.373.0282 Boehringer Ingelheim Investigational Site

    Vero Beach, Florida

  • 502.373.0214 Boehringer Ingelheim Investigational Site

    Weston, Florida

  • 502.373.0161 Boehringer Ingelheim Investigational Site

    Augusta, Georgia

  • 502.373.0193 Boehringer Ingelheim Investigational Site

    Augusta, Georgia

  • 502.373.0201 Boehringer Ingelheim Investigational Site

    Augusta, Georgia

  • 502.373.0223 Boehringer Ingelheim Investigational Site

    Conyers, Georgia

  • 502.373.0268 Boehringer Ingelheim Investigational Site

    Sandersville, Georgia

  • 502.373.0245 Boehringer Ingelheim Investigational Site

    Savannah, Georgia

  • 502.373.0199 Boehringer Ingelheim Investigational Site

    Tucker, Georgia

  • 502.373.0162 Boehringer Ingelheim Investigational Site

    Valdosta, Georgia

  • 502.373.0203 Boehringer Ingelheim Investigational Site

    Pocatello, Idaho

  • 502.373.0244 Boehringer Ingelheim Investigational Site

    Burbank, Illinois

  • 502.373.0272 Boehringer Ingelheim Investigational Site

    Chicago, Illinois

  • 502.373.0217 Boehringer Ingelheim Investigational Site

    Olympia Fields, Illinois

  • 502.373.0270 Boehringer Ingelheim Investigational Site

    Des Moines, Iowa

  • 502.373.0167 Boehringer Ingelheim Investigational Site

    Monroe, Louisiana

  • 502.373.0158 Boehringer Ingelheim Investigational Site

    Shreveport, Louisiana

Showing 40 of 732 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.